Uncategorized
BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million. OpRegen® is currently in a Phase I/IIa clinical study,